Articles From: Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease to Avery Dennison and EVRYTHNG to Make Products Smart


ALISO VIEJO, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended June 30, 2014 after market close on Tuesday, August 5, 2014.
Sign-up for Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference Call investment picks
200 Patient Phase II Clinical Trial to Begin During Third Calendar Quarter of 2014 Second FDA Division Supports Expedited Development Path for AVP-786 ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder investment picks
--Study to Utilize Sequential Parallel Comparison Design to Minimize Placebo Response, Same Design Utilized in AVP-923 Phase II Study in Agitation in Alzheimer's Disease--
Sign-up for Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder investment picks
- Significantly Improved Agitation in 220-Patient 10-week Study - - Company Plans to Meet with FDA to Discuss Initiation of Pivotal Development Program - - Data to be Presented at the American Neurological Association Meeting in October - ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease investment picks
--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population--
Sign-up for Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update investment picks
- Meeting and Webcast to Begin at 7:30 a.m. Eastern Time - ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014 investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Participate in Two Conferences in August investment picks
ALISO VIEJO, Calif.
Sign-up for Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference investment picks
http://media.marketwire.com/attachments/201408/78611_HPLogo.jpg http://media.marketwire.com/attachments/201107/554_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140086&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Avaya and HP to Deliver Expanded Communications Services to the Enterprise investment picks
VANCOUVER , Aug.
Sign-up for Avcorp announces 2014 Second Quarter Financial Results investment picks
Avcorp announces appointment of Chief Executive Officer for its group of companies Canada NewsWire VANCOUVER , Oct.
Sign-up for Avcorp announces appointment of Chief Executive Officer for its group of companies investment picks
Avcorp appoints new director Canada NewsWire VANCOUVER , July 11, 2014 /CNW/ - Avcorp Industries Inc. (TSX: AVP) (the "Company" or "Avcorp") announces today the appointment of Mr.
Sign-up for Avcorp appoints new director investment picks
SCHAUMBURG, Ill., July 21, 2014 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB:WCUI), today announced that wholly-owned subsidiary StealthCo, Inc. has completed an annual agreement with Aveda, a division of Estée Lauder (NYSE:EL) , for the use of Stealth Mark's integrated security products and services within Aveda's supply chain.
Sign-up for Aveda Signs Annual Agreement With Stealth Mark for Brand Protection investment picks
2014/10/9
Miami's Fourth Most-Visited Attraction Expands Amenities for International Visitors AVENTURA, Fla.
Sign-up for Aventura Mall Launches International Shipping Service investment picks
NEW YORK , Aug 1, 2014 /PRNewswire/ -- Avenue Income Credit Strategies Fund (NYSE: ACP) (the " Fund ") announced that it filed a preliminary registration statement with the Securities and Exchange Commission relating to the potential offering of additional common shares of beneficial interest of the Fund (the " Shares ") pursuant to a potential rights offering.
Sign-up for Avenue Income Credit Strategies Fund Announces Filing For A Potential Rights Offering investment picks
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund August Monthly Dividend investment picks
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund October Monthly Dividend investment picks
NEW YORK , July 29, 2014 /PRNewswire/ -- Avenue Income Credit Strategies Fund (NYSE: ACP) , a closed-end management investment company, today announced that portfolio data as of June 30, 2014 , including performance, top ten largest holdings, top five industry holdings, and certain portfolio weightings, is now available to the public on the Fund's website at www.avenuecapital.com under "Strategies – Avenue Income Credit Strategies Closed-End Fund." For more information or to request a hard copy of this data please call: 1-877-525-7330.
Sign-up for Avenue Income Credit Strategies Fund Portfolio Data investment picks
NEW YORK , Aug.
Sign-up for Avenue Income Credit Strategies Fund September Monthly Dividend investment picks
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Sign-up for AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress investment picks
AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million.
Sign-up for AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility investment picks
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2 nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada.
Sign-up for AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain.
Sign-up for AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress investment picks
AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
Sign-up for AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan investment picks
http://media.marketwire.com/attachments/201409/275460_EVRYTHNGlogo.jpeg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1143874&ProfileId=051205&sourceType=1 MENTOR, OH and LONDON, UNITED KINGDOM --
Sign-up for Avery Dennison and EVRYTHNG to Make Products Smart investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease to Avery Dennison and EVRYTHNG to Make Products Smart
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices